Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice.
Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice.
复制标题
人类多能干细胞衍生的间充质干细胞可预防小鼠过敏性气道炎症
DOI：
10.1002/stem.1241
复制
发表时间：
2012-12
期刊：
影响因子：
5.2
通讯作者：
Fu, Qing-Ling
中科院分区：
文献类型：
--
作者：
Sun, Yue-Qi;Deng, Meng-Xia;He, Jia;Zeng, Qing-Xiang;Wen, Weiping;Wong, David S. H.;Tse, Hung-Fat;Xu, Geng;Lian, Qizhou;Shi, Jianbo;Fu, Qing-Ling
我们以前发现，间充质干细胞（MSC）来源于人类诱导的多能干细胞（iPSCs）发挥免疫调节作用的Th 2介导的过敏性鼻炎在体外。然而，它们在哮喘和过敏性鼻炎动物模型中的作用尚不清楚。在这项研究中，我们开发了卵清蛋白（OVA）诱导的过敏性炎症的小鼠模型，在上和下呼吸道，并评估了人iPSC-MSC和骨髓来源的MSC（BM-MSC）的全身给药对过敏性炎症的影响。我们的结果表明，在激发阶段之前用iPSC-MSC和BM-MSC两者治疗保护动物免受大多数过敏特异性病理变化。这种保护包括抑制肺中的炎性细胞浸润和粘液产生，减少鼻中的嗜酸性粒细胞浸润，以及减少支气管肺泡和鼻灌洗液中的炎性细胞浸润。此外，在攻击阶段之前用iPSC-MSC或BM-MSC处理导致Th 2免疫球蛋白的血清水平降低（例如，IgE）和降低的Th 2细胞因子水平，包括支气管肺泡和/或鼻灌洗液中的白细胞介素（IL）-4、IL-5或IL-13。当在致敏阶段之前用人iPSC-MSC预处理动物时，观察到类似的治疗效果。这些数据表明，iPSC-MSCs可用作成人MSCs治疗哮喘和过敏性鼻炎的替代策略。干细胞2012;30：2692-2699
We previously found that mesenchymal stem cells (MSCs) derived from human-induced pluripotent stem cells (iPSCs) exerted immunomodulatory effects on Th2-mediated allergic rhinitis in vitro. However, their contribution to the asthma and allergic rhinitis in animal models remains unclear. In this study, we developed a mouse model of ovalbumin (OVA)-induced allergic inflammation in both the upper and lower airways and evaluated the effects of the systemic administration of human iPSC-MSCs and bone marrow-derived MSCs (BM-MSCs) on allergic inflammation. Our results showed that treatments with both the iPSC-MSCs and BM-MSCs before the challenge phase protected the animals from the majority of allergy-specific pathological changes. This protection included an inhibition of inflammatory cell infiltration and mucus production in the lung, a reduction in eosinophil infiltration in the nose, and a decrease in inflammatory cell infiltration in both the bronchoalveolar and nasal lavage fluids. In addition, treatment with iPSC-MSCs or BM-MSCs before the challenge phase resulted in reduced serum levels of Th2 immunoglobulins (e.g., IgE) and decreased levels of Th2 cytokines including interleukin (IL)-4, IL-5, or IL-13 in the bronchoalveolar and/or nasal lavage fluids. Similar therapeutic effects were observed when the animals were pretreated with human iPSC-MSCs before the sensitization phase. These data suggest that iPSC-MSCs may be used as an alternative strategy to adult MSCs in the treatment of asthma and allergic rhinitis. Stem Cells 2012;30:2692–2699
登录
查看更多内容
影响因子：
--
作者：
Kretlow JD;Jin YQ;Liu W;Zhang WJ;Hong TH;Zhou G;Baggett LS;Mikos AG;Cao Y
通讯作者：
Cao Y
DOI：
10.1111/j.1365-2222.2010.03685.x
发表时间：
2011-04
期刊：
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
影响因子：
--
作者：
Brown JM;Nemeth K;Kushnir-Sukhov NM;Metcalfe DD;Mezey E
通讯作者：
Mezey E
影响因子：
14.2
作者：
Broide, David H.;Finkelman, Fred;Rothenberg, Marc E.
通讯作者：
Rothenberg, Marc E.
DOI：
10.1073/pnas.0910720107
发表时间：
2010-03-23
影响因子：
11.1
作者：
Nemeth, Krisztian;Keane-Myers, Andrea;Mezey, Eva
通讯作者：
Mezey, Eva
影响因子：
3.1
作者：
Crisostomo, Paul R.;Wang, Meijing;Meldrum, Daniel R.
通讯作者：
Meldrum, Daniel R.